Literature DB >> 33256044

The Mechanisms of Benefit of High-Flow Nasal Therapy in Stable COPD.

Massa Zantah1, Aloknath Pandya1, Michael R Jacobs1, Gerard J Criner1.   

Abstract

High-flow nasal therapy (HFNT) is a unique system that delivers humidified, heated oxygen-enriched air via nasal cannula at high flow rates. It is a promising therapy for chronic obstructive pulmonary disease (COPD) patients. Several studies have examined the physiologic effects of this therapy in the patient population and have revealed that it improves mucociliary clearance, reduces nasopharyngeal dead space, and subsequently increases CO2 washout. It also improves alveolar recruitment and gas exchange. These mechanisms may explain the promising results observed in recently published studies that examined the role of HFNT in stable COPD patients.

Entities:  

Keywords:  COPD; HFNC; chronic obstructive pulmonary disease; high flow nasal cannula

Year:  2020        PMID: 33256044      PMCID: PMC7760186          DOI: 10.3390/jcm9123832

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  38 in total

1.  Humidification performance of two high-flow nasal cannula devices: a bench study.

Authors:  Yusuke Chikata; Masayo Izawa; Nao Okuda; Taiga Itagaki; Emiko Nakataki; Mutsuo Onodera; Hideaki Imanaka; Masaji Nishimura
Journal:  Respir Care       Date:  2014-08       Impact factor: 2.258

Review 2.  Use of Nasal High Flow in Stable COPD: Rationale and Physiology.

Authors:  Lara Pisani; Maria Laura Vega
Journal:  COPD       Date:  2017-05-01       Impact factor: 2.409

Review 3.  Does high-flow nasal cannula oxygen improve outcome in acute hypoxemic respiratory failure? A systematic review and meta-analysis.

Authors:  Si-Ming Lin; Kai-Xiong Liu; Zhi-Hong Lin; Pei-Hong Lin
Journal:  Respir Med       Date:  2017-08-09       Impact factor: 3.415

4.  Reductions in dead space ventilation with nasal high flow depend on physiological dead space volume: metabolic hood measurements during sleep in patients with COPD and controls.

Authors:  Paolo Biselli; Kathrin Fricke; Ludger Grote; Andrew T Braun; Jason Kirkness; Philip Smith; Alan Schwartz; Hartmut Schneider
Journal:  Eur Respir J       Date:  2018-05-30       Impact factor: 16.671

5.  The clinical utility of long-term humidification therapy in chronic airway disease.

Authors:  Harold Rea; Sue McAuley; Lata Jayaram; Jeffrey Garrett; Hans Hockey; Louanne Storey; Glenis O'Donnell; Lynne Haru; Matthew Payton; Kevin O'Donnell
Journal:  Respir Med       Date:  2010-02-09       Impact factor: 3.415

6.  Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure.

Authors:  Tommaso Mauri; Cecilia Turrini; Nilde Eronia; Giacomo Grasselli; Carlo Alberto Volta; Giacomo Bellani; Antonio Pesenti
Journal:  Am J Respir Crit Care Med       Date:  2017-05-01       Impact factor: 21.405

7.  Prognosis of severely hypoxemic patients receiving long-term oxygen therapy.

Authors:  P Dubois; J Jamart; J Machiels; F Smeets; J Lulling
Journal:  Chest       Date:  1994-02       Impact factor: 9.410

8.  Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial.

Authors:  John F Fraser; Amy J Spooner; Kimble R Dunster; Chris M Anstey; Amanda Corley
Journal:  Thorax       Date:  2016-03-25       Impact factor: 9.139

9.  Evaluation by various methods of the physiological mechanism of a high-flow nasal cannula (HFNC) in healthy volunteers.

Authors:  Miyuki Okuda; Nobuya Tanaka; Kazuyuki Naito; Takao Kumada; Koji Fukuda; Yuto Kato; Yuto Kido; Yutaro Okuda; Ryuji Nohara
Journal:  BMJ Open Respir Res       Date:  2017-07-20

10.  Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure.

Authors:  Line Hust Storgaard; Hans-Ulrich Hockey; Birgitte Schantz Laursen; Ulla Møller Weinreich
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.